According to the report published by Zion Market Research, global demand for the Bacterial Conjunctivitis Drug market was valued at approximately USD 1.90 Billion in 2019 and is expected to generate revenue of around USD 2.27 Billion by end of 2026, growing at a CAGR of around 2.56% between 2020 and 2026.
Global Bacterial Conjunctivitis Drug Market: Overview
Conjunctivitis is a communicable disease. It is also known as pink eye in the United States and the madras eye in India. Conjunctivitis is an inflammation of the conjunctiva. Conjunctivitis is caused by bacteria, viruses, and allergens. It is a highly contagious disease, spread easily through direct contact of any object like a towel, napkin, or by coughing and sneezing. Bacterial Conjunctivitis Drug is caused mainly by both gram-positive bacteria and gram-negative bacteria. Common bacteria responsible for conjunctivitis are staphylococcus aureus, Pseudomonas, Serratia marcescens, Haemophilus influenza, etc.
Symptoms of Bacterial Conjunctivitis Drugs are reddening of the eyes, excess tears, thick yellow discharge, itching, burning sensation, blurred vision and increase sensitivity towards the light. Treatment includes using antibiotics both systemic and topical. Sometime Povidone-iodine 1.25% ophthalmic solution is also used in African countries like utopia, Uganda as an alternative of antibiotics due to its less cost.
Global Bacterial Conjunctivitis Drug Market: Growth Factors
The bacterial Conjunctivitis Drug market is driven by the increasing incidence of conjunctivitis patients across the globe. The exact epidemiology of this disease is difficult to estimate due to its high incidence and low prevalence. Moreover, continuous increasing incidences of Bacterial Conjunctivitis Drug are responsible for market growth, Bacterial Conjunctivitis Drug accounts for more than 50% of the cases. Nonetheless, ongoing research and development in the healthcare sector coupled with advancement in medical technologies are expected to open growth avenues for the market over the years.
Global Bacterial Conjunctivitis Drug Market: Segmentation
The global Bacterial Conjunctivitis Drug market can be divided into the treatment type, route of administration, disease type, and end user. Based on the treatment type, the market is divided into Fluoroquinolones, Macrolides, Aminoglycosides, and Others. Based on the route of administration type, the market is divided into topical, oral, and intravitreal. Topical antibiotics is predicted to have the largest market share as it is considered to be most effective in reducing the period of conjunctivitis. Based on disease type, the market is divided into acute bacterial conjunctivitis and chronic bacterial conjunctivitis. Based on the end user, the market is divided into hospitals and clinics.
Region-wise, the global market is segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Global Bacterial Conjunctivitis Drug Market: Regional Analysis
The report provides detailed segmentation of the Bacterial Conjunctivitis Drug market based on product segment and regional segment. Geographically, the market has been segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Demand has been analyzed and forecasts based on the current trends for six years. North America was the leading segment of the Bacterial Conjunctivitis Drug market followed by Europe in 2015. The Bacterial Conjunctivitis Drug market is expected to witness the good growth in the Asia-Pacific region, especially in India and China in the coming years due to the rising population and pandemic nature of conjunctivitis diseases.
Global Bacterial Conjunctivitis Drug Market: Competitive Players
Some main participants of the Bacterial Conjunctivitis Drug market are Hoffmann-La Roche Ltd, Perrigo Company plc, Merck & Co. Inc., Akorn Inc., Valeant Pharmaceuticals International Inc., Pfizer Inc., InSite Vision, Bayer AG, Novartis AG, Allergan plc, Bausch & Lomb, Santen Pharmaceutical CO. LTD., Daiichi Sankyo, Inc., Teva Pharmaceutical Industries Ltd., and Trivitron Healthcare among others.
Bacterial Conjunctivitis Drug Market: Regional Segment Analysis
- North America
- The U.S.
- Canada
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Frequently Asked Questions
The Bacterial Conjunctivitis Drug market is driven by the increasing incidence of conjunctivitis patients across the globe. The exact epidemiology of this disease is difficult to estimate due to its high incidence and low prevalence. Moreover, continuous increasing incidences of Bacterial Conjunctivitis Drug are responsible for market growth, Bacterial Conjunctivitis Drug accounts for more than 50% of the cases.
According to Zion Market Research, global demand for the Bacterial Conjunctivitis Drug market was valued at approximately USD 1.90 Billion in 2019 and is expected to generate revenue of around USD 2.27 Billion by end of 2026, growing at a CAGR of around 2.56% between 2020 and 2026.
The region of North America is anticipated to contribute substantially towards the overall Bacterial Conjunctivitis Drug market share during the estimated timeframe.
